Gullans Steven R. Ph.d. - Net Worth and Insider Trading
Gullans Steven R. Ph.d. Net Worth
The estimated net worth of Gullans Steven R. Ph.d. is at least $164,679 dollars as of 2024-11-05. Gullans Steven R. Ph.d. is the Director of Tetraphase Pharmaceuticals Inc and owns about 74,675 shares of Tetraphase Pharmaceuticals Inc (TTPH) stock worth over $164,285. Gullans Steven R. Ph.d. is also the Interim President & CEO of NeuroBo Pharmaceuticals Inc and owns about 155 shares of NeuroBo Pharmaceuticals Inc (NRBO) stock worth over $394. Details can be seen in Gullans Steven R. Ph.d.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Gullans Steven R. Ph.d. has not made any transactions after 2018-02-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Gullans Steven R. Ph.d.
Gullans Steven R. Ph.d. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Gullans Steven R. Ph.d. owns 4 companies in total, including NeuroBo Pharmaceuticals Inc (NRBO) , Aileron Therapeutics Inc (ALRN) , and Tetraphase Pharmaceuticals Inc (TTPH) among others .
Click here to see the complete history of Gullans Steven R. Ph.d.’s form 4 insider trades.
Insider Ownership Summary of Gullans Steven R. Ph.d.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NRBO | NeuroBo Pharmaceuticals Inc | 2018-02-08 | director |
| ALRN | Aileron Therapeutics Inc | 2017-06-28 | 10 percent owner |
| TTPH | Tetraphase Pharmaceuticals Inc | 2014-06-12 | director |
 | | 2021-06-16 | director |
Gullans Steven R. Ph.d. Latest Holdings Summary
Gullans Steven R. Ph.d. currently owns a total of 2 stocks. Among these stocks, Gullans Steven R. Ph.d. owns 74,675 shares of Tetraphase Pharmaceuticals Inc (TTPH) as of May 19, 2014, with a value of $164,285 and a weighting of 99.76%. Gullans Steven R. Ph.d. also owns 155 shares of NeuroBo Pharmaceuticals Inc (NRBO) as of February 8, 2018, with a value of $394 and a weighting of 0.24%.
Latest Holdings of Gullans Steven R. Ph.d.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TTPH | Tetraphase Pharmaceuticals Inc | 2014-05-19 | 74,675 | 2.20 | 164,285 |
| NRBO | NeuroBo Pharmaceuticals Inc | 2018-02-08 | 155 | 2.54 | 394 |
Holding Weightings of Gullans Steven R. Ph.d.
Gullans Steven R. Ph.d. Form 4 Trading Tracker
According to the SEC Form 4 filings, Gullans Steven R. Ph.d. has made a total of 0 transactions in Tetraphase Pharmaceuticals Inc (TTPH) over the past 5 years. The most-recent trade in Tetraphase Pharmaceuticals Inc is the acquisition of 1,250 shares on May 19, 2014, which cost Gullans Steven R. Ph.d. around $231,000.
According to the SEC Form 4 filings, Gullans Steven R. Ph.d. has made a total of 0 transactions in NeuroBo Pharmaceuticals Inc (NRBO) over the past 5 years. The most-recent trade in NeuroBo Pharmaceuticals Inc is the acquisition of 12 shares on February 8, 2018, which cost Gullans Steven R. Ph.d. around $500,003.
Insider Trading History of Gullans Steven R. Ph.d.
- 1
Gullans Steven R. Ph.d. Trading Performance
GuruFocus tracks the stock performance after each of Gullans Steven R. Ph.d.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gullans Steven R. Ph.d. is 8.11%. GuruFocus also compares Gullans Steven R. Ph.d.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Gullans Steven R. Ph.d. within 3 months outperforms 4 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Gullans Steven R. Ph.d.'s insider trading performs compared to the benchmark.
Performance of Gullans Steven R. Ph.d.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 25.19 | | | | | |
| Relative Return to S&P 500(%) | 23.31 | | | | | |
Gullans Steven R. Ph.d. Ownership Network
Ownership Network List of Gullans Steven R. Ph.d.
Ownership Network Relation of Gullans Steven R. Ph.d.
Gullans Steven R. Ph.d. Owned Company Details
What does NeuroBo Pharmaceuticals Inc do?
Who are the key executives at NeuroBo Pharmaceuticals Inc?
Gullans Steven R. Ph.d. is the director of NeuroBo Pharmaceuticals Inc. Other key executives at NeuroBo Pharmaceuticals Inc include 10 percent owner Dong-a St Co., Ltd , Acting Chief Financial Officer Marshall H Woodworth , and Interim CEO and President Joseph Hooker .
NeuroBo Pharmaceuticals Inc (NRBO) Insider Trades Summary
Over the past 18 months, Gullans Steven R. Ph.d. made no insider transaction in NeuroBo Pharmaceuticals Inc (NRBO). Other recent insider transactions involving NeuroBo Pharmaceuticals Inc (NRBO) include a net purchase of 5,088,653 shares made by Dong-a St Co., Ltd ,
In summary, during the past 3 months, insiders sold 407 shares of NeuroBo Pharmaceuticals Inc (NRBO) in total and bought 0 shares, with a net sale of 407 shares. During the past 18 months, 407 shares of NeuroBo Pharmaceuticals Inc (NRBO) were sold and 5,089,060 shares were bought by its insiders, resulting in a net purchase of 5,088,653 shares.
NeuroBo Pharmaceuticals Inc (NRBO)'s detailed insider trading history can be found in Insider Trading Tracker table.
NeuroBo Pharmaceuticals Inc Insider Transactions
Gullans Steven R. Ph.d. Mailing Address
Above is the net worth, insider trading, and ownership report for Gullans Steven R. Ph.d.. You might contact Gullans Steven R. Ph.d. via mailing address: C/o Excel Venture Management, Llc, 800 Boylston St., Ste 2825, Boston Ma 02199.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
